SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

CYTK

Cytokinetics, Incorporated
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Monitor for potential downward pressure on CYTK shares as the offering closes May 8, given the dilutive nature. The stock may trade around the $71 offering price near-term. Watch for any post-offering price support from underwriters.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$74.29
T+0 close · May 6, 2026 · via day close
Latest settled
+2.91%
T+60 · $76.45
Vs SPY
−0.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $74.29entry
  2. T+1 · 6mo ago +3.53%α +2.70% · $76.91
  3. T+5 · 6mo ago +3.94%α +2.44% · $77.22
  4. T+20 · 6mo ago −4.82%α −7.95% · $70.71
  5. T+60 · 4mo ago +2.91%α −0.93% · $76.45

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics priced a $700 million public offering of 9.86 million shares at $71.00 per share, with an underwriter option for an additional 1.48 million shares. The offering represents approximately 7.3% dilution to existing shareholders and will close on May 8, 2026.

Key Financial Metrics

Deal Value
$700.0M

Key Facts

  • 9,859,155 shares offered at $71.00/share for ~$700M gross proceeds
  • Underwriters have 30-day option to purchase up to 1,478,873 additional shares
  • Offering represents ~7.3% dilution (8.4% if greenshoe exercised)
  • Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies are joint book-runners
  • Closing expected May 8, 2026

Financial Impact

~$700M gross proceeds, ~7-8% dilution to existing shareholders

dilutionshare count

Risk Factors

  • Equity dilution of ~7-8%
  • Potential overhang from additional shares if greenshoe exercised
  • Use of proceeds not specified, adding uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289552

Track record

46 reports on CYTK

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026